New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTTEVA, LFL, EPD, RBC, JNPR, RIG, MMYT, GCIOn The Fly: Analyst Upgrade Summary
Enterprise Products (EPD) upgraded to Outperform from Neutral at Credit Suisse... Gannett (GCI) upgraded to Equal Weight from Underweight at Barclays... Juniper (JNPR) upgraded to Outperform from Market Perform at Wells Fargo... LATAM Airlines (LFL) upgraded to Strong Buy from Outperform at Raymond James... MakeMyTrip (MMYT) upgraded to Outperform from Perform at Oppenheimer... Regal-Beloit (RBC) upgraded to Outperform from Neutral at RW Baird... Teva (TEVA) upgraded to Neutral from Sell at Goldman... Transocean (RIG) upgraded to Neutral from Sell at Citigroup.
News For EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 11, 2016
08:22 EDTTEVATeva says closing of Actavis Generics business may 'slip into April'
Subscribe for More Information
07:42 EDTTEVATeva sees maintaining current trend in U.S. generic pricing in 2016
Teva (TEVA) says antitrust review ongoing for Actavis (AGN) generics deal. Says potential buyers for divested assets have been identified, integration plans in place. Says U.S. generic prices "continue slightly downward trend," but company does not see the inflationary pricing discussed in the media or the sharp drop in prices other competitors have seen recently. Sees 2016 to maintain current trend in U.S. generic prices. Comments from slides that will be presented on the Q4 earnings conference call.
07:05 EDTTEVATeva says working to close Actavis Generics acquisition by end of Q1
Subscribe for More Information
07:03 EDTTEVATeva sees Q1 adjusted EPS $1.32-$1.36, consensus $1.21
Subscribe for More Information
07:01 EDTTEVATeva reports Q4 adjusted EPS $1.32, consensus $1.29
Subscribe for More Information
05:44 EDTTEVAOptions expected to be active
Subscribe for More Information
February 10, 2016
14:32 EDTTEVANotable companies reporting before tomorrow's open
Subscribe for More Information
09:01 EDTTEVATeva volatility elevated into Q4 and outlook
Teva February weekly call option implied volatility is at 81, February is at 51, March is at 37; compared to its 52-week range of 20 to 41, suggesting large near term price movement into the expected release of Q4 results on February 11.
07:17 EDTJNPRGoldman Sachs to hold a conference
Technology & Internet Conference is being held in San Francisco on February 9-11 with webcasted company presentations to begin on February 10 at 11 am; not all company presentations may be webcasted. Webcast Link
February 9, 2016
18:50 EDTGCIGabelli to vote against Journal Media merger, disagrees with ISS recommendation
In a regulatory filing detailing a 15.63% stake in Journal Media Group (JMG), Gabelli noted it has reviewed the report by proxy advisory firm ISS regarding Journal's proposed merger with Gannett (GCI), and intends to vote against the merger plan for those shares over which it has voting authority. Journal Media's "refusal to disclose its real estate asset valuations, beyond the $5.4M 'excess real estate value' for real estate not used in core operations, is what is truly misleading to shareholders," Gabelli claimed.
11:50 EDTGCIGannett examining parcel-delivery business, WSJ reports
Gannett (GCI) is examining the parcel-delivery business and has reached out to consultants in the parcel industry as early as December, The Wall Street Journal reports, citing sources. According to one source, Gannett also held preliminary talks with Amazon (AMZN) as it considers delivery possibilities. The report notes that Tribute Publishing (TPUB) abandoned a similar idea after briefly testing package delivery with Amazon in the fall. Reference Link
08:08 EDTGCIJournal Media Group says ISS recommends investors vote for merger with Gannett
Journal Media Group (JMG) announced that Institutional Shareholder Services has recommended that Journal Media Group shareholders vote "FOR" the proposed merger between Journal Media Group and Gannett (GCI). ISS stated in its February 8, 2016 report: "A vote FOR this transaction is warranted given the substantial premium, the strength of the sales process, the fact that no superior offers have emerged despite the reasonable breakup fee, and the apparently material downside risks..." The transaction and other matters will be considered at a special meeting for Journal Media Group shareholders on March 1, 2016, at 10 a.m. at Journal Media Group's headquarters at 333 W. State St., Milwaukee, Wisconsin. Journal Media Group shareholders of record as of the close of business on January 21, 2016, are entitled to vote at the special meeting either in person or by proxy. The parties currently expect to complete the proposed transaction promptly following approval by Journal Media Group shareholders and the expiration or termination of the Hart-Scott-Rodino waiting period.
February 8, 2016
17:17 EDTRBCRegal-Beloit sees FY16 adjusted EPS $4.80-$5.20, consensus $5.55
17:16 EDTRBCRegal-Beloit reports Q4 adjusted EPS $1.17, consensus $1.11
Subscribe for More Information
09:34 EDTTEVAPfizer sees decision about potential separation by no later than end 2018
Subscribe for More Information
05:20 EDTRIGTransocean announces customer early terminates Discoverer Deep Seas
Subscribe for More Information
February 2, 2016
08:12 EDTTEVATeva enters into collaborative research agreement with AbCellera
Subscribe for More Information
08:01 EDTTEVATeva, AbCellera enter agreement to discover rare monoclonal antibodies
Teva and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies. Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
February 1, 2016
08:04 EDTTEVATeva Mylan not seeing same negative trends as Sandoz, says Bernstein
After Novartis (NVS) reported weak results for its generics unit, Sandoz, and blamed it on industry trends, Bernstein quotes Mylan (MYL) and Teva (TEVA) as saying that they are seeing only "slight adjustments back to normal levels" from "mildly favorable" results in 2014 and 2015. Bernstein says that Sandoz has lost a number of fairly profitable products and has had fewer approvals than its peers. Bernstein keeps Outperform ratings on Teva and Mylan.
06:41 EDTLFLBrazil mulls removing foreign stake limit for airlines, Reuters reports
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use